Clinical Trials Logo
  1. Home
  2. Bloodstream Infection
  3. NCT05277350

A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects

Bloodstream Infection Clinical Trial

Official title:
A Phase 1, Randomized, Double-Blind, First-In-Human, Dose Escalation Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects

Clinical Trial Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose, dose escalation study in healthy participants, investigating the safety, tolerability, recovery, and PD of multiple oral administrations of SNIPR001.

Clinical Trial Description

Approximately 36 healthy male and female participants will be randomized to one of 3 active oral doses of SNIPR001 or matching placebo, administered twice a day (BID) for 7 days. Subjects will be followed up until 6 months after receiving the last dose of SNIPR001. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05277350
Study type Interventional
Source SNIPR Biome Aps.
Contact
Status Completed
Phase Phase 1
Start date March 24, 2022
Completion date May 1, 2023
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Completed NCT02400268 - Antibiotic Treatment Duration (7 vs 14 Days) Comparison in Blood Stream Infection Causes by Enterobacteriaceae Phase 3
Recruiting NCT04070820 - Combination Treatment for Enterococcus Faecalis Bacteriemia Multicenter, Observational Study"
Completed NCT03147807 - BetaLACTA® Test for Early De-escalation of Empirical Carbapenems in Pulmonary, Urinary and Bloodstream Infections in ICU N/A
Completed NCT05411315 - Pragmatic Randomized Trial for Arterial Catheters in the Critical Care Environment N/A
Enrolling by invitation NCT05880069 - Clinical Outcomes in Patients With Infection by Resistant Microorganism
Terminated NCT04250168 - Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response
Terminated NCT04876430 - Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems Phase 2/Phase 3
Completed NCT03255759 - Actionable Results: Bloodstream Infection Molecular Assay Evaluation N/A
Active, not recruiting NCT03744728 - Genotypic Versus Phenotypic Susceptibility Testing of Positive Blood Cultures N/A
Terminated NCT00680459 - Ethanol Locks for the Treatment of Central Venous Line Infections Phase 3
Recruiting NCT04839653 - Efficacy and Safety of Selective Digestive Decontamination in the ICU With High Rates of Antibiotic-resistant Bacteria N/A
Recruiting NCT03896893 - Neonatal Bacterial Colonization Study N/A
Recruiting NCT00843804 - Surveillance for Nosocomial Infections in Pediatric Cancer Patients N/A
Completed NCT00467272 - Catheter Related - Gram Positive Bloodstream Infections Phase 2
Recruiting NCT04658017 - GARNET™ Filter (GARNET Device) IDE Used in Chronic Hemodialysis Patients With a Bloodstream Infection N/A
Completed NCT04710212 - Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies
Not yet recruiting NCT06271031 - Process Mapping and Data Collection to Inform a Computer Simulation Model of Hospitalised Patients With Bloodstream Infection, Sepsis and Systemic Infection
Not yet recruiting NCT03991793 - Granzyme A in Patients With E. Coli Bacteremic Urinary Tract Infections
Completed NCT00870623 - Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections